Company
Octant
Next-generation small molecule therapeutics
Also known as Octant, Inc.
- Status
- Operatingas of 2026-09-18
- Business model
- B2B
- Legal name
- Octant, Inc.
- octant.bio (opens in a new tab)
- LinkedIn (opens in a new tab)
- X (opens in a new tab)
- Careers (opens in a new tab)
Claim, correct or request removal
Record updated 28 September 2026
About
Most drug programs focus on binding molecules to a purified “target” protein, hoping that binding will drive a desired downstream function. Octant engineers biology and chemistry at massive scales to modulate the function itself, targeting complex cellular mechanisms that drive disease. We've focused these efforts internally on correcting diseases of protein misfolding and mistrafficking.
Funding snapshot
- Total raised
- $315KSEC form D sum, as of 2026-09-28Source (opens in a new tab)
- Latest round
- Round, $315K2014-12-30
Funding rounds
- Round, 2014
- $315K2014-12-30, SEC form D sold, 11 investors
Products
- Other
- OCT-980
Loading relationship preview